BR112018068702A2 - inibidores bicíclicos em ponte de menin-mll e métodos de uso - Google Patents

inibidores bicíclicos em ponte de menin-mll e métodos de uso

Info

Publication number
BR112018068702A2
BR112018068702A2 BR112018068702A BR112018068702A BR112018068702A2 BR 112018068702 A2 BR112018068702 A2 BR 112018068702A2 BR 112018068702 A BR112018068702 A BR 112018068702A BR 112018068702 A BR112018068702 A BR 112018068702A BR 112018068702 A2 BR112018068702 A2 BR 112018068702A2
Authority
BR
Brazil
Prior art keywords
methods
menin
mll
bridged bicyclic
bicyclic inhibitors
Prior art date
Application number
BR112018068702A
Other languages
English (en)
Inventor
Dmitry Borkin
Tomasz Cierpicki
Jolanta Grembecka
Szymon Klossowski
Liansheng Li
Jonathan Pollock
Pingda Ren
Yi Wang
Tao Wu
Original Assignee
Kura Oncology Inc
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kura Oncology Inc, Univ Michigan Regents filed Critical Kura Oncology Inc
Publication of BR112018068702A2 publication Critical patent/BR112018068702A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

o presente relatório provê métodos para a inibição da interação de menin com mll1, mll2 e oncoproteínas de fusão de mll. os métodos são úteis para o tratamento de leucemia, cânceres sólidos, diabetes e outras doenças dependentes da atividade de mll1, mll2, proteínas de fusão de mll e/ou menin. são também providas composições para uso nestes métodos.
BR112018068702A 2016-03-16 2017-03-15 inibidores bicíclicos em ponte de menin-mll e métodos de uso BR112018068702A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662309362P 2016-03-16 2016-03-16
US201662431387P 2016-12-07 2016-12-07
PCT/US2017/022535 WO2017161002A1 (en) 2016-03-16 2017-03-15 Bridged bicyclic inhibitors of menin-mll and methods of use

Publications (1)

Publication Number Publication Date
BR112018068702A2 true BR112018068702A2 (pt) 2019-01-15

Family

ID=59851929

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068702A BR112018068702A2 (pt) 2016-03-16 2017-03-15 inibidores bicíclicos em ponte de menin-mll e métodos de uso

Country Status (17)

Country Link
US (2) US10752639B2 (pt)
EP (1) EP3429585B1 (pt)
JP (1) JP7000333B2 (pt)
KR (1) KR102419524B1 (pt)
CN (1) CN109640987B (pt)
AU (1) AU2017235462B2 (pt)
BR (1) BR112018068702A2 (pt)
CA (1) CA3015845A1 (pt)
HK (1) HK1258821A1 (pt)
IL (1) IL261625B (pt)
MA (1) MA43823A (pt)
MX (1) MX2018011092A (pt)
PH (1) PH12018501955A1 (pt)
SG (1) SG11201807834WA (pt)
TW (1) TWI743096B (pt)
WO (1) WO2017161002A1 (pt)
ZA (1) ZA201805845B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
MA43823A (fr) 2016-03-16 2018-11-28 Kura Oncology Inc Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
MX2018013433A (es) 2016-05-02 2019-07-18 Univ Michigan Regents Piperidinas como inhibidores de menina.
MX2019002962A (es) 2016-09-14 2019-07-04 Janssen Pharmaceutica Nv Inhibidores espirobiciclicos de la interaccion de menina-mll.
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
JP7142010B2 (ja) 2016-12-15 2022-09-26 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のアゼパン阻害剤
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液***恶性肿瘤和尤因肉瘤的方法
KR20190133224A (ko) 2017-03-31 2019-12-02 더 리젠츠 오브 더 유니버시티 오브 미시간 공유 메닌 억제제로서의 피페리딘
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN110204552B (zh) * 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
WO2019189732A1 (ja) 2018-03-30 2019-10-03 大日本住友製薬株式会社 光学活性な架橋型環状２級アミン誘導体
WO2020069027A1 (en) * 2018-09-26 2020-04-02 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
CN110964016B (zh) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 氨基降茨烷衍生物及其制备方法与应用
BR112021007421A2 (pt) * 2018-12-06 2021-08-03 Daiichi Sankyo Company, Limited derivado de cicloalcano-1,3-diamina
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
EP3924329A2 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
JP2023522166A (ja) * 2020-04-07 2023-05-29 シンダックス ファーマシューティカルズ， インコーポレイテッド メニン阻害剤とｃｙｐ３ａ４阻害剤との組合せ、およびその使用方法
JP2024518434A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
EP4334320A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
JP2024517945A (ja) 2021-05-14 2024-04-23 シンダックス ファーマシューティカルズ， インコーポレイテッド メニン－ｍｌｌ相互作用の阻害剤
WO2022253167A1 (en) 2021-06-01 2022-12-08 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
EP4355747A1 (en) 2021-06-17 2024-04-24 JANSSEN Pharmaceutica NV (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CA3229150A1 (en) 2021-08-20 2023-02-23 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cance
WO2023220098A1 (en) * 2022-05-09 2023-11-16 Syndax Pharmaceuticals, Inc. Menin-mll inhibitors for the treatment of cancer
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US949A (en) 1838-09-27 Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton
US5861A (en) 1848-10-17 Locking umbrella and parasol
US510A (en) 1837-12-07 soeel
US5863A (en) 1848-10-17 Matthias p
US1007727A (en) 1908-02-17 1911-11-07 Oscar F Onken Auxiliary table-top.
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE4239169A1 (de) 1992-11-21 1994-05-26 Merck Patent Gmbh Cyclobutan - Benzol - Derivate
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
ES2183905T3 (es) 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
PT923585E (pt) 1996-07-18 2002-08-30 Pfizer Inibidores a base de fosfinato de metaloproteases de matriz
JP3333870B2 (ja) 1996-07-26 2002-10-15 国土交通省北陸地方整備局長 草刈機
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5866562A (en) 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
DK0950059T3 (da) 1997-01-06 2004-11-01 Pfizer Cycliske sulfonderivater
PL335027A1 (en) 1997-02-03 2000-03-27 Pfizer Prod Inc Derivatives of arylsulphonylamino hydroxamic acid
EP0966438A1 (en) 1997-02-07 1999-12-29 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
CN101100472A (zh) 2001-04-30 2008-01-09 美国拜尔公司 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
WO2004030671A2 (en) 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
WO2004030672A1 (en) 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
BRPI0408988A (pt) 2003-03-31 2006-03-28 Predix Pharmaceuticals Holding composto de piperidinilamino-tieno[2,3-d]pirimidina
JP5335191B2 (ja) 2003-08-22 2013-11-06 デンドレオン コーポレイション Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法
US20050123906A1 (en) 2003-11-06 2005-06-09 Rana Tariq M. Protein modulation
EP1768964A1 (en) 2004-07-06 2007-04-04 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
JP4981794B2 (ja) * 2005-06-03 2012-07-25 アボット・ラボラトリーズ シクロブチルアミン誘導体
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281771A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
WO2007026024A2 (en) 2005-09-02 2007-03-08 Tibotec Pharmaceuticals Ltd. Benzodiazepines as hcv inhibitors
ATE444345T1 (de) 2005-09-19 2009-10-15 Merck Patent Gmbh Cyclobutan- und spiroä3.3üheptanverbindungen
FR2891829A1 (fr) 2005-10-12 2007-04-13 Sanofi Aventis Sa Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
JP2009521479A (ja) 2005-12-21 2009-06-04 アボット・ラボラトリーズ 抗ウイルス化合物
AU2007236116A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having MnKl /Mnk2 inhibiting activity for pharmaceutical compositions
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
WO2008070303A2 (en) 2006-10-19 2008-06-12 The University Of Chicago Therapeutics to inhibit mll-menin interaction for treating leukemia
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
WO2008099019A1 (en) 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors
FR2913017A1 (fr) 2007-02-23 2008-08-29 Cerep Sa Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
US8309726B2 (en) 2007-03-19 2012-11-13 Council Of Scientific & Industrial Research Substituted piperazine compounds of formula 8
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
US20080293699A1 (en) 2007-05-25 2008-11-27 Burnham Institute For Medical Research Inhibitors of thapsigargin-induced cell death
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US20110124649A1 (en) 2007-11-09 2011-05-26 The Johns Hopkins University Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8193203B2 (en) 2008-05-22 2012-06-05 Allergan, Inc. Bicyclic compounds having activity at the CXCR4 receptor
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
EP2328871B1 (en) 2008-08-25 2020-04-01 Novartis AG Hedgehog pathway modulators
EP2320904A4 (en) 2008-09-10 2011-09-14 Kalypsys Inc AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
EP2451813B1 (en) 2009-07-08 2014-10-01 Leo Pharma A/S Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
EP2459533A4 (en) 2009-07-30 2013-01-16 Univ Singapore SMALL MOLECULE INHIBITORS OF ISOPRENYLCYSTEIN CARBOXYL METHYLTRANERASE WITH POTENTIAL ANTICANCING ACTIVITY
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
SG183233A1 (en) 2010-02-22 2012-09-27 Merck Patent Gmbh Hetarylaminonaphthyridines
MX2013001970A (es) 2010-08-20 2013-08-09 Hutchison Medipharma Ltd Compuestos de pirrolopirimidina y usos de los mismos.
WO2013019966A1 (en) * 2011-08-04 2013-02-07 Allergan, Inc. Aromatic bycyclic derivatives as cxcr4 receptor modulators
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
CN103833759A (zh) * 2012-11-23 2014-06-04 华东理工大学 作为blk、flt3抑制剂的蝶啶酮衍生物及其应用
JP2016512514A (ja) 2013-03-13 2016-04-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
US9212180B2 (en) * 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
ES2702951T3 (es) * 2014-04-04 2019-03-06 Syros Pharmaceuticals Inc Inhibidores de quinasas dependientes de ciclina 7 (cdk7)
WO2015191701A1 (en) 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2016040330A1 (en) * 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
JP2018538330A (ja) 2015-12-22 2018-12-27 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
AU2017212572A1 (en) 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
MA43823A (fr) 2016-03-16 2018-11-28 Kura Oncology Inc Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
MX2018013433A (es) 2016-05-02 2019-07-18 Univ Michigan Regents Piperidinas como inhibidores de menina.
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
SI3468966T1 (sl) 2016-06-10 2021-03-31 Vitae Pharmaceuticals, Llc Zaviralci interakcije menin-MLL
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
WO2018050686A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
KR102536029B1 (ko) 2016-09-16 2023-05-23 비타이 파마슈티컬즈, 엘엘씨 메닌-ｍｌｌ 상호작용의 억제제

Also Published As

Publication number Publication date
US20210107917A1 (en) 2021-04-15
EP3429585A1 (en) 2019-01-23
US20190092783A1 (en) 2019-03-28
AU2017235462A1 (en) 2018-09-27
EP3429585B1 (en) 2021-11-24
MX2018011092A (es) 2018-11-22
TW201742870A (zh) 2017-12-16
CN109640987A (zh) 2019-04-16
JP2019508426A (ja) 2019-03-28
TWI743096B (zh) 2021-10-21
MA43823A (fr) 2018-11-28
IL261625B (en) 2021-08-31
KR102419524B1 (ko) 2022-07-08
HK1258821A1 (zh) 2019-11-22
US11555041B2 (en) 2023-01-17
AU2017235462B2 (en) 2021-07-01
KR20180127406A (ko) 2018-11-28
JP7000333B2 (ja) 2022-02-10
SG11201807834WA (en) 2018-10-30
WO2017161002A1 (en) 2017-09-21
PH12018501955A1 (en) 2019-06-17
ZA201805845B (en) 2023-03-29
US10752639B2 (en) 2020-08-25
CA3015845A1 (en) 2017-09-21
IL261625A (en) 2018-10-31
CN109640987B (zh) 2022-12-02
EP3429585A4 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
BR112018068702A2 (pt) inibidores bicíclicos em ponte de menin-mll e métodos de uso
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
MY186712A (en) Methods and compositions for inhibiting the interaction of menin with mll proteinss
MX2021010482A (es) Compuestos y metodos para la degradacion mejorada de proteinas especificas.
BR112015022602A2 (pt) composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos
CO2018011668A2 (es) Neoantígenos y métodos de su uso
WO2018119441A8 (en) Egfr proteolysis targeting chimeric molecules and associated methods of use
MX2021012926A (es) Moduladores de la proteolisis basados en imida y metodos de uso asociados.
BR112016027722A8 (pt) compostos contendo grupo autoimulativo e seu uso
MX2017012805A (es) Complejo de unión a antígenos con actividad agonista y métodos de uso.
MX2018000360A (es) Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
CL2021001735A1 (es) Inhibidores irreversibles de la interacción menina-mll.
MX2017015605A (es) Moduladores de proteolisis basados en imida y metodos de uso asociados.
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
MX2022009478A (es) Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
TR201909887T4 (tr) ERK inhibitörleri olarak tieno[2,3-c]pirol-4-on türevleri.
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
BR112019007365A2 (pt) métodos e composições para imunoterapia com tusc2
WO2017075170A8 (en) Methods of measuring factor d activity and potency of factor d inhibitors
EP3925979A3 (en) Fgfr-tacc fusion proteins and methods thereof
BR112019003834A2 (pt) compostos contendo monoterpenoides / fenilpropanóides e métodos de sua fabricação e uso como herbicidas
EA201892082A1 (ru) Мостиковые бициклические ингибиторы менин-mll и способы применения

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements